Assessment of endothelial function in patients with nonalcoholic fatty liver disease
First Online: 03 June 2012 Received: 19 March 2012 Accepted: 21 May 2012 DOI:
Cite this article as: Colak, Y., Senates, E., Yesil, A. et al. Endocrine (2013) 43: 100. doi:10.1007/s12020-012-9712-1 Abstract
In this study, we aimed to evaluate the endothelial functions in patients with nonalcoholic fatty liver disease (NAFLD). In this observational case–control study, a total of 51 patients with NAFLD in study group and a total of 21 with age- and sex-equivalent individuals in control group were enrolled. In both patients and control groups, levels of asymmetric dimethylarginine (ADMA), systemic endothelial function (brachial artery flow-mediated dilation) (FMD) and carotid artery intima-media thickness (C-IMT) were measured. FMD and C-IMT were evaluated by vascular ultrasound. Plasma levels of ADMA were measured by ELISA. C-IMT was significantly higher in patients with NAFLD group than control group (0.67 ± 0.09 vs. 0.52 ± 0.11 mm,
P < 0.001). The average C-IMT measurements were found in groups of control, simple steatosis, and NAFLD with (borderline and definite) NASH as 0.52 ± 0.11, 0.63 ± 0.07, and 0.68 ± 0.1 mm, respectively. The differences between groups were significant ( P < 0.001). Measurement of brachial artery FMD was significantly lower in patients with NAFLD group compared to control group (7.3 ± 4.8 vs. 12.5 ± 7.1 %, P < 0.001). FMD measurements in groups of control, the simple steatosis, and NAFLD with NASH as 12.5 ± 7.1, 9.64 ± 6.63, and 7.03 ± 4.57 %, respectively, and the differences were statistically significant ( P < 0.001). The increase in C-IMT and decrease in FMD was independent from metabolic syndrome and it was also more evident in patients with simple steatosis and NASH compared to control group. There was no significant difference between the control and NAFLD groups in terms of plasma ADMA levels (0.61 ± 0.11 vs. 0.69 ± 0.37 μmol/L, P = 0.209). Our data suggested that NAFLD is associated with endothelial dysfunction and increased earlier in patients with atherosclerosis compared to control subjects. Keywords Endothelial dysfunction Carotid artery intima-media thickness Brachial artery flow-mediated dilatation Asymmetric dimethylarginine References
G. Marchesini, E. Bugianesi, G. Forlani et al., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology
, 917–923 (2003)
N. Rafiq, Z.M. Younossi, Evaluation and management of nonalcoholic fatty liver disease. Clin. Liver Dis.
, 249–266 (2009)
G. Perseghin, The role of non-alcoholic fatty liver disease in cardiovascular disease. Dig. Dis.
, 210–213 (2010)
H. Chatrath, R. Vuppalanchi, N. Chalasani, Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin. Liver Dis.
, 22–29 (2012)
K. Cusi, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology
, 711–725 (2012)
R. Wang, Q. Lu, J. Feng et al., Coexistence of non-alcoholic fatty liver disease with elevated Alanine aminotransferase is associated with insulin resistance in young Han males. Endocrine
, 70–75 (2012)
L.A. Adams, S. Harmsen, J.L. St Sauver et al., Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol.
, 1567–1573 (2010)
G.E. Roĭtberg, O.O. Sharkhun, T.I. Ushakova, Non-alcoholic fatty liver disease as an atherosclerosis risk factor. Eksp. Klin. Gastroenterol.
, 20–24 (2010)
G. Targher, C.P. Day, E. Bonora, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med.
, 1341–1350 (2010)
P.O. Bonetti, L.O. Lerman, A. Lerman, Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol.
, 168–175 (2003)
H. Cai, D.G. Harrison, Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res.
, 840–844 (2000)
O.T. Raitakari, M. Juonala, M. Kähönen et al., Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA
, 2277–2283 (2003)
M.W. Lorenz, H.S. Markus, M.L. Bots, M. Rosvall, M. Sitzer, Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation
, 459–467 (2007)
D.S. Celermajer, K.E. Sorensen, V.M. Gooch et al., Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet
, 1111–1115 (1992)
R. Johannides, W.K. Haefeli, L. Linder et al., Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation
, 1314–1319 (1995)
D.S. Celermajer, M.R. Adams, P. Clarkson et al., Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med.
, 150–154 (1996)
J.A. Panza, A.A. Quyyumi, J.E. Brush Jr, S.E. Epstein, Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med.
, 22–27 (1990)
M.C. Corretti, T.J. Anderson, E.J. Benjamin et al., International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol.
, 257–265 (2002)
R.H. Böger, S.M. Bode-Böger, A. Szuba et al., Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation
, 1842–1847 (1998)
J.D. Horowitz, T. Heresztyn, An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
, 42–50 (2007)
A.J. Sanyal, AGA technical review on nonalcoholic fatty liver disease. Gastroenterology
, 1705–1725 (2002)
S.M. Grundy, H.B. Brewer Jr, J.I. Cleeman et al., American Heart Association and National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation
, 433–438 (2004)
ACE/ADA Task Force on Inpatient Diabetes, American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Diabetes Care
, 1955–1962 (2006)
S.S. Moon, Y.S. Lee, S.W. Kim, Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine (2012) (Epub ahead of print)
D.E. Kleiner, E.M. Brunt, M. Van Natta et al., Nonalcoholic steatohepatitis clinical research network: design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology
, 1313–1321 (2005)
J. Davignon, P. Ganz, Role of endothelial dysfunction in atherosclerosis. Circulation
, 27–32 (2004)
A. Sciacqua, M. Perticone, S. Miceli et al., Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr. Metab. Cardiovasc. Dis.
, 485–491 (2011)
O. Senturk, O. Kocaman, S. Hulagu et al., Endothelial dysfunction in Turkish patients with non-alcoholic fatty liver disease. Intern. Med. J.
, 183–189 (2008)
G. Targher, L. Bertolini, R. Padovani et al., Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care
, 1325–1330 (2006)
E. Scorletti, P.C. Calder, C.D. Byrne, Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine
, 332–343 (2011)
N. Villanova, S. Moscatiello, S. Ramilli et al., Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology
, 473–478 (2005)
T. Kasumov, J.M. Edmison, S. Dasarathy et al., Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism
, 776–781 (2011)
T. Dogru, H. Genc, S. Tapan et al., Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes Res. Clin. Pract.
, 47–52 (2012)
H. Yki-Jarvinen, J. Westerbacka, The fatty liver and insulin resistance. Curr. Mol. Med.
, 287–295 (2005)
A.J. Hanley, K. Williams, A. Festa et al., Liver markers and development of the metabolic syndrome. The ınsulin resistance atherosclerosis study. Diabetes
, 3140–3147 (2005)
N. Chalasani, M.A. Deeg, D.W. Crabb, Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol.
, 1497–1502 (2004)
J.W. Haukeland, J.K. Damås, Z. Konopski et al., Systemic inflammation in non-alcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol.
, 1167–1174 (2006)
G. Musso, R. Gambino, M. Durazzo et al., Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology
, 1175–1183 (2005)
G. Targher, L. Bertolini, S. Rodella et al., Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin. Endocrinol.
, 679–683 (2006)
CrossRef Copyright information
© Springer Science+Business Media, LLC 2012